JP2008539169A5 - - Google Patents

Download PDF

Info

Publication number
JP2008539169A5
JP2008539169A5 JP2008507834A JP2008507834A JP2008539169A5 JP 2008539169 A5 JP2008539169 A5 JP 2008539169A5 JP 2008507834 A JP2008507834 A JP 2008507834A JP 2008507834 A JP2008507834 A JP 2008507834A JP 2008539169 A5 JP2008539169 A5 JP 2008539169A5
Authority
JP
Japan
Prior art keywords
treatment
immunostimulant
medicament
disease
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008507834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008539169A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/014720 external-priority patent/WO2006113792A2/en
Publication of JP2008539169A publication Critical patent/JP2008539169A/ja
Publication of JP2008539169A5 publication Critical patent/JP2008539169A5/ja
Pending legal-status Critical Current

Links

JP2008507834A 2005-04-19 2006-04-19 疾患における免疫学的介入のための一価および多価合成多糖類抗原 Pending JP2008539169A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67280705P 2005-04-19 2005-04-19
PCT/US2006/014720 WO2006113792A2 (en) 2005-04-19 2006-04-19 Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease

Publications (2)

Publication Number Publication Date
JP2008539169A JP2008539169A (ja) 2008-11-13
JP2008539169A5 true JP2008539169A5 (enExample) 2009-06-04

Family

ID=37115904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008507834A Pending JP2008539169A (ja) 2005-04-19 2006-04-19 疾患における免疫学的介入のための一価および多価合成多糖類抗原

Country Status (8)

Country Link
US (1) US20090214598A1 (enExample)
EP (2) EP1874343A4 (enExample)
JP (1) JP2008539169A (enExample)
KR (1) KR20070122563A (enExample)
CN (1) CN101448517A (enExample)
AU (1) AU2006236294A1 (enExample)
CA (1) CA2605321A1 (enExample)
WO (1) WO2006113792A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067026A2 (en) 2006-09-29 2008-06-05 Michigan Technological University Purification of synthetic oligomers
WO2009059328A2 (en) * 2007-11-02 2009-05-07 The Johns Hopkins University Multi- component l2 vaccine for prevention of human papillomavirus infection
US20110262473A1 (en) * 2008-07-07 2011-10-27 The University Of Melbourne Synthetic vaccine component
WO2012047639A2 (en) 2010-09-27 2012-04-12 Michigan Technological University Purification of synthetic oligonucleotides
BR112017021970A2 (pt) * 2015-04-17 2018-07-10 Symic Ip Llc bioconjugados e usos dos mesmos
AU2018298422B2 (en) 2017-07-04 2023-04-06 CureVac SE Novel nucleic acid molecules
AU2018298224B2 (en) * 2017-07-07 2024-08-15 Symic Ip, Llc Synthetic bioconjugates
SG11202100814YA (en) 2018-09-19 2021-02-25 Univ Nanyang Tech Biohybrid peptidoglycan oligomers
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
SU727647A1 (ru) 1977-11-02 1980-04-15 Институт биоорганической химии им.М.М.Шемякина Гликопептиды,обладающие противоопухолевой активностью и способ их получени
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US6024964A (en) 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5864008A (en) 1988-03-25 1999-01-26 James; Stephen Peptides derived from foot-and-mouth disease virus, pharmaceutical compositions, and methods for using the peptides
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US6423315B1 (en) 1993-03-03 2002-07-23 The University Of Tennessee Research Corp. Synthetic peptide for treatment of autoimmune arthritis
AUPM885194A0 (en) 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
ATE213499T1 (de) 1994-11-18 2002-03-15 Neurocrine Biosciences Inc Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
WO1997005889A1 (en) * 1995-08-03 1997-02-20 Slesarev Vladimir I Non-specific vaccination by d-amino-acid containing compounds
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
IL120503A0 (en) 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
US6107021A (en) 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
NZ513482A (en) 1999-02-05 2003-08-29 Univ Melbourne T helper cell epitodes derived from canine distemper virus for producing an immune response in an animal
FR2797202B1 (fr) 1999-08-02 2001-10-26 Genomic Equipement pour l'extraction automatique d'acides nucleiques
WO2003014957A1 (en) 2001-08-03 2003-02-20 Porto Ranelli, S.A. Identification of users on a network
US20030033351A1 (en) 2001-08-10 2003-02-13 Aleta Ricciardi Group proxy and method for grouping services in a distributed computing application
WO2003015815A1 (en) * 2001-08-21 2003-02-27 The Brigham And Women's Hospital, Inc. Improved conjugate vaccines
WO2003070761A1 (en) 2002-02-19 2003-08-28 Yeda Research And Development Co. Ltd. Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
CN1200590C (zh) 2002-03-01 2005-05-04 华为技术有限公司 一种实现gsm与cdma网络信令互通的方法
EP1494687A2 (en) * 2002-03-08 2005-01-12 Eli Lilly And Company Immunomodulatory polymeric antigens for treating inflammatory pathogies
EP1543039B1 (en) 2002-08-12 2011-07-13 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes
CA2494193A1 (en) 2002-08-12 2004-02-19 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes
US7420037B2 (en) 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
AU2004229458B2 (en) 2003-04-11 2009-11-19 Antigenics, Inc. Improved heat shock protein-based vaccines and immunotherapies
AU2004280329B2 (en) * 2003-09-17 2011-03-24 Eli Lilly And Company Synthetic polysaccharide antigens for immunological intervention in disease

Similar Documents

Publication Publication Date Title
JP2011006431A5 (enExample)
HRP20150770T1 (hr) Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin
JP2012255026A5 (enExample)
ME02558B (me) Inhibitori replikacije virusa gripa
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2011157741A3 (en) Human antibody drug conjugates against tissue factor
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
JP2015057451A5 (enExample)
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
JP2013014622A5 (enExample)
EA201071204A1 (ru) Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
JP2020097577A5 (enExample)
JP2016510326A5 (enExample)
JP2012517449A5 (enExample)
JP2014503593A5 (enExample)
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
JP2009537554A5 (enExample)
HRP20171742T4 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
JP2008539169A5 (enExample)
JP2010500284A5 (enExample)
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
JP2013523758A5 (enExample)